Cost-minimization analysis comparing subcutaneous trastuzumab at home with intravenous trastuzumab for HER2-positive breast cancer in Singapore

Autor: Yanting Ouyang, Han Yi Lee, Fun Loon Leong, Han Jieh Tey, Vivianne Shih, Elaine Hsuen Lim, Nicholas Graves

Publikováno v: Therapeutic Advances in Medical Oncology, Vol 16 (2024)

Background: Trastuzumab (Herceptin) can be administered intravenously (IV Herceptin) and subcutaneously, with similar efficacy and safety, but with differences in dosage and costs. Previous studies have evaluated the costs of both treatment approache

Externí odkaz: https://doaj.org/article/03f27213a67e4211a9d6378a7dffd58f

Successful therapeutic rechallenge after a severe episode of high dose methotrexate‑induced choreoathetosis: A case report

Autor: Chee Leong Cheng, Lip Leong Chong, Vivianne Shih, Nagavalli Somasundaram, Miriam Tao, Evelyn Wong, Leonard Tan, Jason Yongsheng Chan, Soon Thye Lim, Choon Kiat Ong, Daryl Ming Zhe Cheah, Eileen Yi Ling Poon, Mohamad Farid, James B. K. Khoo, Sheryl Lyn Lucero Santos‑Banta, Tiffany Tang

Publikováno v: Molecular and Clinical Oncology

Methotrexate (MTX) is an essential chemotherapy drug used in the treatment of malignancies, but it is known to cause complications to the central nervous system. We report a case of severe MTX neurotoxicity in an adult presenting with choreoathetosis

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::459930944baa023aa16b09d21c778b3b
https://doi.org/10.3892/mco.2019.1898

A systematic review of patient-reported outcome instruments of dermatologic adverse events associated with targeted cancer therapies

Autor: Vivianne Shih, Yi Ling Teo, Katja Schindler, Rene Jean Bensadoun, Elvio G. Russi, Raymond Javan Chan, Jennifer N. Choi, Cesar O. Freytes, Laura Curr Beamer, Peter Arne Gerber, Bernardo Leon Rapoport, Michael C. Cameron, Eric Roeland, Jane Bryce, Alexandre Chan, Benjamin C. Garden, Joel B. Epstein, Mario E. Lacouture, Nicole R. LeBoeuf, Judith E. Raber-Durlacher, Vincent Sibaud, Christine B. Boers-Doets

Publikováno v: Supportive Care in Cancer, 23(8), 2231-2244. Springer Verlag
Chan, A, Cameron, M C, Garden, B, Boers-Doets, C B, Schindler, K, Epstein, J B, Choi, J, Beamer, L, Roeland, E, Russi, E G, Bensadoun, R J, Teo, Y L, Chan, R J, Shih, V, Bryce, J, Raber-Durlacher, J, Gerber, P A, Freytes, C O, Rapoport, B, LeBoeuf, N, Sibaud, V & Lacouture, M E 2015, ' A systematic review of patient-reported outcome instruments of dermatologic adverse events associated with targeted cancer therapies ', Supportive Care in Cancer, vol. 23, no. 8, pp. 2231-2244 . https://doi.org/10.1007/s00520-014-2564-x
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, vol 23, iss 8

PurposeDermatologic adverse events (dAEs) in cancer treatment are frequent with the use of targeted therapies. These dAEs have been shown to have significant impact on health-related quality of life (HRQoL). While standardized assessment tools have b

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::22c8c42c89003dba15606ddfcf8a34c7
https://doi.org/10.1007/s00520-014-2564-x

Clinical pharmacy services and research for lymphoma patients at a cancer center

Autor: Lita Chew, Kevin Tay, Joen Chiang, Soon Thye Lim, Richard Quek, Vivianne Shih, Miriam Tao, Alexandre Chan

Publikováno v: Journal of Oncology Pharmacy Practice. 19:24-30

At the National Cancer Centre Singapore, which is currently the largest ambulatory cancer centre in Singapore, clinical pharmacists have taken upon responsibilities to provide direct pharmaceutical care in the center’s lymphoma team since 2006. Giv

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d9bbdeee63dbe749764a9126fdc1554
https://doi.org/10.1177/1078155212449031

A prospective study to evaluate the feasibility and economic benefits of rapid infusion rituximab at an Asian cancer center

Autor: Miriam Tao, Soon Thye Lim, Joen Chiang, Vivianne Shih, Siew Wan Hee, Alexandre Chan

Publikováno v: International Journal of Hematology. 91:826-830

Rituximab (Mabthera®) is currently approved for the treatment of multiple subtypes of CD20-expressing, B-cell, non-Hodgkin’s lymphoma. This study aimed to investigate whether rapid infusion of rituximab over 90 min is feasible without compromising

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc2bda326f7a3b0666e86bf0e21de00f
https://doi.org/10.1007/s12185-010-0583-z